Gumarontinib Tablets

DRUG2 trials

Sponsors

Haihe Biopharma Co., Ltd.

Conditions

Advanced Solid Tumor

Phase 1

A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors

CompletedNCT03457532

Haihe Biopharma Co., Ltd.Advanced Solid Tumor

Start: 2017-12-16End: 2023-09-22Updated: 2024-11-01

Study to Evaluate the Safety and Anti-tumor Activity of SCC244

CompletedNCT03466268

Haihe Biopharma Co., Ltd.Advanced Solid Tumor

Start: 2017-09-14End: 2023-01-09Updated: 2024-10-09

Related Papers

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib.

2024-07-311 citations

A phase I clinical trial to assess the safety, pharmacokinetics, and antitumor activity of glumetinib (SCC244) in patients with advanced non-small cell lung cancers (NSCLCs).

Journal of Clinical Oncology2020-05-202 citations